Home Newsfeeds Janney Montgomery Scott Downgrades FB Financial to Neutral

Janney Montgomery Scott Downgrades FB Financial to Neutral

Janney Montgomery Scott analyst Feddie Stickland downgrades FB Financial (NYSE:FBK) from Buy to Neutral.

byBenzinga Newsdesk

December 14, 2022

1 minute read

Janney Montgomery Scott analyst Feddie Stickland downgrades FB Financial (NYSE:FBK) from Buy to Neutral.

Cantor Fitzgerald Maintains Neutral on HEXO, Lowers Price Target to C$0.26

By Benzinga Newsdesk

November 30, 12:24 PM

Cantor Fitzgerald analyst Pablo Zuanic maintains HEXO (TSX:HEXO) with a Neutral and lowers the price target from C$0.35 to C$0.26.

TSX:HEXO

News

‘Samsung says customer data stolen in July data breach’ – TechCrunch

By Benzinga Newsdesk

September 2, 2:02 PM

https://techcrunch.com/2022/09/02/samsung-data-breach/

CHKP

Why Are LogicBio Therapeutics Shares Skyrocketing Today?

By Vandana Singh

October 3, 7:21 AM

AstraZeneca Plc’s (NASDAQ:AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ:LOGC) for $2.07 per share. Both boards have unanimously approved…

AZN

Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial

By Vandana Singh

May 16, 2:50 PM

Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in

LGND

Janney Montgomery Scott Downgrades FB Financial to Neutral

Related Posts

Cantor Fitzgerald Maintains Neutral on HEXO, Lowers Price Target to C$0.26

‘Samsung says customer data stolen in July data breach’ – TechCrunch

Why Are LogicBio Therapeutics Shares Skyrocketing Today?

Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial